Tempest Therapeutics
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy (NCT06680258) | Tempest Therapeutics | 2025-12-01 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
Track Tempest Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.